<SEC-DOCUMENT>0000939767-24-000002.txt : 20240108
<SEC-HEADER>0000939767-24-000002.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108090606
ACCESSION NUMBER:		0000939767-24-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240102
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		24518611

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>exel-20240102.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2024 Workiva--><!--r:745486aa-ecca-4c80-b851-6f13daa2549c,g:5b81fc4a-82b9-419e-8977-ded20b57d1c3,d:154e59aa7fdc4d0db86c4cebe79877ff--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20240102</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20240102.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:20pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">January 2, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:47pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="text-align:center"><img src="exel-20240102_g1.jpg" alt="Exelixis_Logo_RGB_2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"/></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">EXELIXIS, INC.</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"></td><td style="width:38.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-30235</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">04-3257395</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1851 Harbor Bay Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Alameda</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94502</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices) (Zip Code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">837-7000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code) </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div style="margin-bottom:5pt;margin-top:3pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:39.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2024, Exelixis, Inc. (Exelixis or the Company) issued a press release announcing its preliminary unaudited financial results for the fiscal year ended December 29, 2023, providing financial guidance for the fiscal year ending January 3, 2025, and delivered an update on its business. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The preliminary unaudited financial results contained in the press release do not present all information for an understanding of Exelixis&#8217; financial condition as of December 29, 2023 and its results of operations for the fiscal year ended December 29, 2023. The audit of Exelixis&#8217; financial statements for the fiscal year ended December 29, 2023 is ongoing and could result in changes to the information in the press release. The press release also announced that Exelixis will report its audited financial results for the fiscal year ended December 29, 2023 on February 6, 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission (SEC) made by Exelixis, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.05. Costs Associated with Exit or Disposal Activities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2024, the Company&#8217;s Board of Directors (the Board) authorized a restructuring plan (the Plan) to reduce its workforce and rebalance the Company&#8217;s cost structure in alignment with its strategic priorities, including reducing real estate commitments and costs and terminating certain licensing partnerships.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Plan, the Company currently estimates that it will incur aggregate charges of approximately $25 million, $13.5 million of which relate to the workforce reduction. The Company expects these costs will be substantially recognized during the first quarter of 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan will result in a workforce reduction of approximately 175 employees or 13% of our total headcount at the end of 2023. The Plan is expected to be implemented and substantially completed during the first quarter of 2024.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing estimates of the charges the Company expects to incur under the Plan are subject to assumptions and actual charges may differ from such estimates.</span></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_1649267441812"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2024, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Exelixis, the Board increased the size of the Board to 13 members and appointed Mary C. Beckerle, Ph.D. and S. Gail Eckhardt, M.D. to the Board to fill the newly created vacancies, effective immediately. There are no related party transactions between the Company and Drs. Beckerle and Eckhardt that are subject to disclosure under Item 404(a) of Regulation S-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As non-employee directors, Drs. Beckerle and Eckhardt will be entitled to receive the standard cash and equity compensation for non-employee directors described under the caption &#8220;Compensation of Directors&#8221; in Exelixis&#8217; 2023 proxy statement, filed with the SEC on May 1, 2023, and as set forth on Exhibit 10.3 to the Company&#8217;s quarterly report on Form 10-Q for the quarterly period ended September 29, 2023, filed with the SEC on November 1, 2023. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the indemnification provided for directors in Exelixis&#8217; Bylaws, Exelixis intends to enter into its standard form of Indemnification Agreement with each of Drs. Beckerle and Eckhardt, a copy of which was previously filed as Exhibit 10.1 to Exelixis&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February 18, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, Alan M. Garber, M.D., Ph.D., informed the Company that he has decided not to stand for re-election to the Board when his term expires at the 2024 annual meeting of stockholders. Dr. Garber will continue to serve as a director until the 2024 annual meeting of stockholders and his decision was not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_1649267441826"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2024, Exelixis announced that the Board authorized the repurchase of up to $450 million of its common stock before the end of 2024. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference only with respect to the discussion in the section titled &#8220;Announcement of $450 Million Share Repurchase Program for 2024.&#8221;</span></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_549755814015"></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d) &#160;&#160;&#160;&#160;Exhibits.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240108exhibit991.htm">Press Release</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240108exhibit991.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240108exhibit991.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240108exhibit991.htm">ated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20240108exhibit991.htm"> January 7, 2024</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i154e59aa7fdc4d0db86c4cebe79877ff_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 8, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey J. Hessekiel</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jeffrey J. Hessekiel</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel <br/>and Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exel20240108exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if65acf81d01947818cf90ce613022f3f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:9pt"><img alt="exelixis_logoxrgbx2023.jpg" src="exelixis_logoxrgbx2023.jpg" style="height:47px;margin-bottom:5pt;vertical-align:text-bottom;width:177px"></div><div style="padding-right:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contacts&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Susan Hubbard</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">EVP, Public Affairs &#38; Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-8194</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">shubbard&#64;exelixis.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chris Senner</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">650-837-7240</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">csenner&#64;exelixis.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Contact&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Hal Mackins</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">For Exelixis, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">415-994-0040</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">hal&#64;torchcommunications.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product revenues for fiscal year 2023 &#8211;</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Fiscal year 2024 net product revenues guidance of $1,650 million - $1,750 million&#59; </font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2024 R&#38;D expense guidance of $925 million - $975 million &#8211;</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Appointment of two new board members, Mary C. Beckerle, Ph.D., and Gail Eckhardt, M.D., with extensive drug development and corporate governance expertise &#8211;</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Implementing corporate restructuring to focus R&#38;D resources on clinical stage and IND-enabling activities to maximize pipeline success and operational efficiency &#8211;</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Board of Directors authorized $450 million share repurchase in 2024 after successful completion of $550 million share repurchase in 2023 &#8211;</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8211; Presentation and webcast at 2024 J.P. Morgan Healthcare Conference tomorrow, Monday, January 8th at 4&#58;30 p.m. PT &#47; 7&#58;30 p.m. ET &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ALAMEDA, Calif. &#8211; January 7, 2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis, Inc. (Nasdaq&#58; EXEL) today announced its preliminary unaudited financial results for the fiscal year 2023, provided financial guidance for fiscal year 2024 and delivered an update on its business. Exelixis expects 2024 to be a year of pipeline progress as it advances its portfolio of promising biotherapeutics and small molecule candidates recently highlighted at its </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2023 R&#38;D Day</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and pursues potential near-term label expansion opportunities for CABOMETYX&#174; (cabozantinib).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- more -</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:87.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Preliminary FY 2023 Financial Results, 2024 Financial Guidance, and Key Priorities and Milestones</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page 2 of 6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 7, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Preliminary Fiscal Year 2023 Financial Results &#38; 2024 Financial Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is providing the following preliminary unaudited 2023 financial results and financial guidance for 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:39.713%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Year 2023</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2024 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#126; $1,830 million</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,825 million - $1,925 million</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues </font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#126; $1,630 million</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,650 million - $1,750 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#126; 4.5%</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4% - 5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#126; $1,045 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$925 million - $975 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#126; $545 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$425 million - $475 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;a</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20% - 22%</font></div></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exelixis&#8217; 2024 net product revenues guidance range includes the impact of a U.S. wholesale acquisition cost increase of 2.2% for both CABOMETYX&#174; and COMETRIQ&#174; effective on January 1, 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $34 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $40 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $72 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes $60 million of non-cash stock-based compensation expense.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preliminary results not yet available.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preliminary 2023 financial information presented in this press release has not been audited and is subject to change. The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Supported by strong revenues from cabozantinib, our global oncology franchise, Exelixis is advancing an innovative pipeline of differentiated product candidates that can improve standards of care for cancer patients,&#8221; said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. &#8220;Our 2024 plans include filing data-driven label expansions for CABOMETYX, accelerating the development of zanzalintinib, XB002, and XL309, and moving three promising preclinical programs into clinical development. The success of our internal drug discovery efforts as highlighted at our recent R&#38;D Day compels a rebalancing of our investment priorities from early-stage research to product development activities. Exelixis will therefore implement a corporate restructuring that will concentrate R&#38;D resources to advance our emerging pipeline, and maintain positive cash flow to support an additional $450 million share repurchase following successful completion of the $550 million share repurchase in 2023. We are taking these steps with the conviction that they are necessary for our continued progress toward the company&#8217;s goal of delivering an innovative pipeline of biotherapeutics and small molecules to help patients with cancer and create value for all of our stakeholders.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate Updates</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate Restructuring to Rebalance Resources to Drive Pipeline Success&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis will implement a corporate restructuring that will prioritize the advancement of the company&#8217;s deep pipeline of clinical and near-clinical programs. As a result, Exelixis is reducing its workforce by approximately 175 employees or 13 percent. Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- more -</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:87.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Preliminary FY 2023 Financial Results, 2024 Financial Guidance, and Key Priorities and Milestones</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page 3 of 6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 7, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Appointment of Two New Board Members&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> As part of the company&#8217;s continued board refreshment plan announced last year, Exelixis is announcing two new appointments to its Board of Directors, effective January 5, 2024&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mary C. Beckerle, Ph.D., Chief Executive Officer of the Huntsman Cancer Institute and Distinguished Professor of Biological and Oncological Sciences at the University of Utah. Since 2006, Dr. Beckerle has had responsibility for the vision, strategic direction, and management of the University&#8217;s oncology programs, including research, care, education, and community outreach. A noted cell biologist and cancer researcher, Dr. Beckerle&#8217;s work on cytoskeletal dynamics and cell adhesion has led to important advances both in basic and translational science. In addition to Exelixis, Dr. Beckerle serves as an independent director of Johnson &#38; Johnson and Huntsman Corporation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gail Eckhardt, M.D., Associate Dean of Experimental Therapeutics at Baylor College of Medicine and Associate Director of Translational Research at the College&#8217;s Dan L. Duncan Comprehensive Cancer Center. Dr. Eckhardt is a recognized leader in translational medicine relative to oncology with a particular emphasis on preclinical and early clinical development of molecularly targeted therapies and combination regimens to treat colorectal and other gastrointestinal cancers. She currently serves on the Board of Syros Pharmaceuticals, and as an academic advisor for eleven NCI-designated Cancer Centers, among other roles. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, current Exelixis board member Alan M. Garber, M.D., Ph.D., has notified the company that he will not stand for reelection at the company&#8217;s 2024 Annual Meeting of Stockholders later this spring due to his expanded responsibilities at Harvard University. Having served as Harvard&#8217;s provost and chief academic officer since 2011, last week Dr. Garber became the University&#8217;s interim president.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Announcement of $450 Million Share Repurchase Program for 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Exelixis Board of Directors authorized the repurchase of up to an additional $450 million of the company&#8217;s common stock in 2024. As of the end of 2023, Exelixis completed the repurchase of 26.2 million shares of the company&#8217;s common stock, or 8% of shares outstanding, for a total of $550 million, fulfilling its commitments under the 2023 Share Repurchase Program announced in March 2023. Share repurchases under the 2024 program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis&#8217; common stock and general market conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Anticipated 2024 Cabozantinib Milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cabozantinib Pivotal Trial Data Readouts and Anticipated U.S. Regulatory Filings&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Detailed data from CONTACT-02, the phase 3 pivotal trial evaluating the combination of cabozantinib and atezolizumab versus a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable, extrapelvic soft tissue disease who have been previously treated with one NHT, will be the subject of an oral presentation at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium on January 25, 2024. Positive top-line results indicating that the trial met one of its primary endpoints of progression-free survival (PFS) were announced in August 2023, and the study continues toward the next analysis of the second primary endpoint of overall survival (OS), which is anticipated in 2024. Exelixis will continue its discussions with the U.S. Food and Drug Administration (FDA) on a potential regulatory path forward for cabozantinib in mCRPC. Also anticipated in 2024 is a potential regulatory filing for cabozantinib in advanced neuroendocrine tumors (NET) based on positive results from the pivotal phase 3 CABINET study, which evaluates cabozantinib versus placebo in patients with either advanced pancreatic NET (pNET) or extra-pancreatic NET (epNET) and is conducted by The Alliance for Clinical Trials in Oncology (The Alliance). </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- more -</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:87.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Preliminary FY 2023 Financial Results, 2024 Financial Guidance, and Key Priorities and Milestones</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page 4 of 6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 7, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Detailed data presented at the European Society for Medical Oncology Congress 2023 showed that the study met its primary endpoint, demonstrating dramatic improvement in PFS for patients treated with cabozantinib in both the pNET and epNET cohorts. Exelixis is working with The Alliance to discuss a potential regulatory filing with the FDA and will provide an update when appropriate.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Anticipated Outcome of Cabozantinib Abbreviated New Drug Application (ANDA) Litigation with MSN Pharmaceuticals&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The second bench trial for Exelixis&#8217; ongoing ANDA lawsuit against MSN Pharmaceuticals, Inc. concluded in October 2023, and Exelixis anticipates a ruling from the United States District Court for the District of Delaware in the first half of 2024. Exelixis is confident in its cabozantinib patent estate and is vigorously defending the patents at issue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Upcoming Development Milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Zanzalintinib Clinical Progress Anticipated in 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Zanzalintinib is a third-generation tyrosine kinase inhibitor (TKI) that Exelixis believes can become the vascular endothelial growth factor receptor TKI of choice as solid tumor therapeutic landscapes continue to evolve. Exelixis is executing on three ongoing pivotal trials of zanzalintinib, STELLAR-303, -304, and -305, in forms of colorectal cancer, non-clear cell renal cell carcinoma, and squamous cell carcinoma of the head and neck, respectively. Zanzalintinib is also the subject of three ongoing earlier-stage trials, STELLAR-001, -002, and -009, intended to evaluate its potential in best-in-class combinations and identify indications for future pivotal trials, with priorities defined by emerging data and potential clinical co-funding opportunities. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">XB002 Clinical Progress Anticipated in 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> XB002 is a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC) that Exelixis believes has development potential as a monotherapy and in combination regimens. In 2024, Exelixis is focused on advancing JEWEL-101, the phase 1 study of XB002 alone and in combination with immunotherapy in a variety of solid tumor settings with the goal of prioritizing sensitive tumor types for full development.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">XL309 Clinical Progress Anticipated in 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> XL309 is a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors. Exelixis in-licensed XL309 from Insilico Medicine in September 2023, and the process of transferring stewardship of the program&#8217;s ongoing phase 1 trial to Exelixis was completed in the fourth quarter of 2023. Exelixis&#8217; clinical development priorities for XL309 include accelerating its development as a potential therapy for tumors that have become refractory to PARP inhibitor (PARPi) therapy, including forms of ovarian, breast, and prostate cancers, pursuing potential PARPi combinations, and moving beyond the PARPi market into new areas. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Anticipated Discovery Milestones</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Potential Investigational New Drug (IND) Applications in 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis anticipates moving three programs into clinical development this year, including two biotherapeutics and one small molecule compound. The company expects to file an IND application for the XB010 5T4-MMAE ADC program in the first half of 2024, and expects to file IND applications for the XB628 PD-L1-NKG2A bispecific antibody and XL495 small molecule PKMYT1 inhibitor programs in the second half of 2024 if preclinical data continue to be supportive. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Current Development Candidate (DC) Programs and New DC Designations expected in 2024&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Exelixis has two DC programs that may be the subjects of IND filings in 2025, including the XB371 TF-Topoisomerase I inhibitor ADC and XB064 ILT-2 monoclonal antibody programs, and the XB033 IL13Ra2-Topoisomerase I inhibitor ADC that may be the subject of an IND filing in 2026. In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- more -</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:87.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Preliminary FY 2023 Financial Results, 2024 Financial Guidance, and Key Priorities and Milestones</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page 5 of 6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 7, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Presentation and Webcast</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., will provide a corporate overview and discuss the company&#8217;s preliminary fiscal year 2023 financial results, 2024 financial guidance, and key priorities and milestones for 2024 during the company&#8217;s presentation at the 42nd Annual J.P. Morgan Healthcare Conference beginning at 4&#58;30 p.m. PT &#47; 7&#58;30 p.m. ET on Monday, January 8, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To access the webcast link, log onto </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and proceed to the Event Calendar page under the Investors &#38; News heading. A replay will also be available at the same location for at least 30 days.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">About Exelixis</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX&#174; (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.exelixis.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;ExelixisInc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (Twitter), like </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis, Inc.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on Facebook and follow </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exelixis</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on LinkedIn.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements and Preliminary Financial Results</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, including, without limitation, statements related to&#58; Exelixis&#8217; expectation that 2024 will be a year of pipeline progress as it advances its portfolio of promising biotherapeutics and small molecule candidates and pursues potential near-term label-expansion opportunities for CABOMETYX&#59; Exelixis&#8217; 2024 financial guidance&#59; Exelixis&#8217; 2024 plans for filing data-driven label expansions for CABOMETYX, accelerating the development of zanzalintinib, XB002 and XL309, and moving three promising preclinical programs into clinical development&#59; Exelixis&#8217; plans and expectations for corporate restructuring in the first quarter of 2024 and for a new $450 million share repurchase program in 2024&#59; Exelixis&#8217; anticipated cabozantinib milestones for 2024, including the presentation of data from CONTACT-02 at ASCO GU later in January 2024, the next analysis of OS data from CONTACT-02, continued discussions with the FDA regarding the potential regulatory path forward for cabozantinib in mCRPC, a potential regulatory filing in 2024 for cabozantinib as a treatment for NET based on positive results from CABINET, and an expected ruling in the ANDA lawsuit against MSN Pharmaceuticals, Inc. in the first half of 2024&#59; Exelixis&#8217; upcoming development milestones for 2024, including clinical progress and priorities for zanzalintinib and Exelixis&#8217; belief that zanzalintinib can become the vascular endothelial growth factor receptor TKI of choice as solid tumor therapeutic landscapes continue to evolve, clinical progress and priorities for XB002 and Exelixis&#8217; belief that XB002 has development potential as a monotherapy and in combination regimens, and clinical progress and priorities for XL309 and Exelixis&#8217; belief that XL309 is a potentially best-in-class small molecule inhibitor of USP1&#59; Exelixis&#8217; anticipated discovery milestones for 2024, including potential IND filings for XB010 in the first half of 2024 and for XB628 and XL495 in the second half of 2024 if preclinical data continue to be supportive, and the designation of two new programs to DC status in 2024, as well as potential IND filings in 2025 for XB371 and XB064&#59; Exelixis&#8217; scientific pursuit to create transformational treatments that give more patients hope for the future&#59; and other statements that are not historical facts. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis&#8217; current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">- more -</font></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.899%"><tr><td style="width:1.0%"></td><td style="width:87.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exelixis Preliminary FY 2023 Financial Results, 2024 Financial Guidance, and Key Priorities and Milestones</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page 6 of 6</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 7, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation&#58; the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis&#8217; and its partners&#8217; ability to obtain or maintain coverage and reimbursement for these products&#59; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products&#59; the level of costs associated with Exelixis&#8217; commercialization, research and development, in-licensing or acquisition of product candidates, and other activities&#59; Exelixis&#8217; ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so&#59; the availability of data at the referenced times&#59; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and&#47;or efficacy in clinical testing&#59; uncertainties inherent in the drug discovery and product development process&#59; Exelixis&#8217; dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved&#59; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere&#59; Exelixis&#8217; continuing compliance with applicable legal and regulatory requirements&#59; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis product candidates&#59; Exelixis&#8217; dependence on third-party vendors for the development, manufacture and supply of its products and product candidates&#59; Exelixis&#8217; ability to protect its intellectual property rights&#59; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis&#8217; marketed products&#59; changes in economic and business conditions&#59; and other factors detailed from time to time under the caption &#8220;Risk Factors&#8221; in Exelixis&#8217; most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis&#8217; other future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, this press release includes Exelixis&#8217; preliminary financial results for the fiscal year ended December 29, 2023. Exelixis is currently in the process of finalizing its financial results for the quarter and fiscal year ended December 29, 2023, and the preliminary financial results presented in this press release are based only upon preliminary information available to Exelixis as of January 7, 2024. Exelixis&#8217; preliminary financial results should not be viewed as a substitute for audited financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Exelixis&#8217; preliminary financial results. Exelixis&#8217; independent registered public accounting firm has not audited or reviewed the preliminary financial results included in this press release or expressed any opinion or other form of assurance on such preliminary financial results. In addition, items or events may be identified or occur after the date of this press release due to the completion of operational and financial closing procedures, final audit adjustments and other developments may arise that would require Exelixis to make material adjustments to the preliminary financial results included in this press release. Therefore, the preliminary financial results included in this press release may differ, perhaps materially, from the financial results that will be reflected in Exelixis&#8217; audited consolidated financial statements for the fiscal year ended December 29, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks.</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>exel-20240102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:745486aa-ecca-4c80-b851-6f13daa2549c,g:5b81fc4a-82b9-419e-8977-ded20b57d1c3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20240102" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20240102">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20240102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>exel-20240102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:745486aa-ecca-4c80-b851-6f13daa2549c,g:5b81fc4a-82b9-419e-8977-ded20b57d1c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_0f311b27-8746-4d94-b20c-95f129d67566_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b1542faa-0693-4797-90cb-19a0cc0fa227_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cb8f5067-6b4d-4bc1-94a5-b1be81efba22_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_61d5938f-1fe5-4212-b7c8-2538c185745b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_781e368d-6e9d-43bd-b9fb-e48e29ecdb70_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3ad88fda-f00b-44fb-9012-7813775e7412_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_58884a4c-83ec-4f63-a487-94f41a53a38d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0a7a8fe2-ba2c-42fe-8b19-28f52ca83c88_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f7d1b617-ec98-4716-b0fb-99231c36948f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5938e843-ed68-4f21-a47b-91de4259efdf_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_28b45d0e-b920-4016-99a8-2bc803e40993_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bafe72d0-acda-4dbe-bff8-b8261105111a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_74235676-c5e2-4ea7-804c-5f69d5461f65_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_39b833e1-35e3-4dce-ab7b-e2d6d3fdc67f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3b40c37f-fa86-4c83-a9ac-a90197c11acb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce677254-5cb1-45bc-9485-1e9852799431_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_da831ad0-5741-4983-bbe5-862184040bbb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f50dafd4-02b0-48ac-a494-c113176b571c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_96f9a27f-b159-43c1-bf58-241817fcea9a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c8518a9e-5701-45b5-b5bf-9090da58eb73_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3251378e-c4ae-4252-8951-0365e4f27bc8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4675914d-4b20-456d-a5f2-4103b1f2245c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_553e6c70-df88-4ca4-ae36-b11e35349e50_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>exel-20240102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:745486aa-ecca-4c80-b851-6f13daa2549c,g:5b81fc4a-82b9-419e-8977-ded20b57d1c3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20240102.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5529c15f-ebda-4490-ba66-885eba39614b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_AmendmentFlag_5529c15f-ebda-4490-ba66-885eba39614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8bfe8986-2490-4c9b-b6e3-db508baccd37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_DocumentPeriodEndDate_8bfe8986-2490-4c9b-b6e3-db508baccd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2065a3d2-f08d-46d8-b17a-73ee40390d55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityRegistrantName_2065a3d2-f08d-46d8-b17a-73ee40390d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4bfa6d50-158f-44af-aaba-fcf5edea86f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityCentralIndexKey_4bfa6d50-158f-44af-aaba-fcf5edea86f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d74e45ed-0081-41dd-b282-4d5ae807380d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityEmergingGrowthCompany_d74e45ed-0081-41dd-b282-4d5ae807380d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ab996b07-9388-4b54-9463-74dfa41725a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_Security12bTitle_ab996b07-9388-4b54-9463-74dfa41725a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eaf85c24-5496-41db-8f9b-a5fcc519067a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_TradingSymbol_eaf85c24-5496-41db-8f9b-a5fcc519067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f4b8e76-b3e7-4768-a381-eaca50da6368" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_SecurityExchangeName_7f4b8e76-b3e7-4768-a381-eaca50da6368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00a6f757-1cf5-46d9-aea6-0c6c41ed1473" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityFileNumber_00a6f757-1cf5-46d9-aea6-0c6c41ed1473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f212d93b-74bc-44cd-a7eb-5c79aa47c673" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f212d93b-74bc-44cd-a7eb-5c79aa47c673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_42b26fb7-20cc-4d00-a3ff-33329268f7fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityTaxIdentificationNumber_42b26fb7-20cc-4d00-a3ff-33329268f7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_26e26159-c4bc-4809-b491-d901a8279b6a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityAddressAddressLine1_26e26159-c4bc-4809-b491-d901a8279b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0aa67370-19b3-4987-aa2d-5475f25caa5c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityAddressCityOrTown_0aa67370-19b3-4987-aa2d-5475f25caa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dde032f3-8e6e-4e88-bad3-8c1fcb456ca4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityAddressStateOrProvince_dde032f3-8e6e-4e88-bad3-8c1fcb456ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a059f326-0dbe-471c-886f-60b95adfaa30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_EntityAddressPostalZipCode_a059f326-0dbe-471c-886f-60b95adfaa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_270e6580-2f13-4b41-ab52-b21d6999afb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_CityAreaCode_270e6580-2f13-4b41-ab52-b21d6999afb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_25c1b903-ca04-4d0d-a056-f3b611f20ded" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_LocalPhoneNumber_25c1b903-ca04-4d0d-a056-f3b611f20ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_964cba12-cb51-44dc-84c3-333329078cae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_WrittenCommunications_964cba12-cb51-44dc-84c3-333329078cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_d1555780-05d4-4d1d-b595-863bdd5a417a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_SolicitingMaterial_d1555780-05d4-4d1d-b595-863bdd5a417a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_612199da-723c-41a6-a4ef-0d404e2128a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_PreCommencementTenderOffer_612199da-723c-41a6-a4ef-0d404e2128a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e1c71f27-96b2-493d-8c34-a19076ebb00a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e1c71f27-96b2-493d-8c34-a19076ebb00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b127fc05-dcd2-40fb-851a-04431278345a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e5eae107-db32-4241-9176-b42414643ebf" xlink:to="loc_dei_DocumentType_b127fc05-dcd2-40fb-851a-04431278345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>exel-20240102_g1.jpg
<TEXT>
begin 644 exel-20240102_g1.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
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M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
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M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
M  !V0O=RUE!%JR;T[J1@F)P5MA68LJI<    >:;;'&Z /S/R0   .RIN6SUG
M?6P Q%,>>/7'JX!RQZ$,ML]Q( B1:M#.F7Y@&3$^B#+7NL2 //EKC&N8 _,_
M)    Y=-M=-+**7 %6M\ZJ+T RJGTF8[     4!ZY1:FH$MHM?7EJ (U<&Y_
M6WT?WY]0!V[Z/S;=/2'F#EOT?F   PKQ;EM7/07HO;TM\38]W;T-)OGG7H V
M!Y:ML-8!;132SFEP!5+?.KF]/@!O3/L3S:>@HPW,:3X =[/11EMWZ)KBO3\2
M<E;03M7C46>TT    'FFVQQN@"T"E[,Z:   #GS?@  AI:M%6F7P RTGT.X[
M=J!B^8\\&N/30#D#T"9;2-B0 //EKC&N8 L$K>V_/0   <T<H  5:WSJHO0#
M*J?29CL    !0'KE%J:@2VBU]>6H %870OH? O$.9_ ?27O9/6$^NX.E  !T
MOY?UJH//'I7K7X?WC+?(^-6M^A?->J8 &P/+5MAK +:*:6<TN!^9YF-L.D@$
MAHF]S/7O\2!U@A1:E:MZ1\F,Q1-W6>DCXL/S*\[TX,_8L5I?D0    >:;;'&
MZ +5Z7M*IH       *HKYU=WH )CUM>OGKL#S\:XQWF -)<K32PZEP !Y\M<
M8US %BU;W%YZ      "K6^=5%Z 953Z3,=@    * ]<HM34"6T6OKRU  Z+\
MG[-2'G'TYL,M0/TM%KGH7S9ECD7&0!QV.]5?GSTCBSC_ "($VH>@?..:.4<2
M  V!Y:ML-8!;132SFEP,7S'FHUQ_8 NWSTG56X  ' G.GT        'FFVQQ
MN@"U>E[2J:       #\BA?7*)<U %K%-,83%>]J? "?M;729Z@  >?+7&-<P
M!8M6]Q>>@      JUOG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !"SJ[MJ
M#74_<  ROR'CEKGH;S5^MJCX5N=']^1LX-S[X"1O-N"V5]Y^?P !L#RU;8:P
M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
MD[+\KQ:T>9T5PD1'L&A)94XL'LG+#HKYR\<FTD!"?K$5%/X67$R)B'D0]]@B
M!+T2LOT25(!(*)A'!03H90=S9(KQ++H04$]C7\NH#I%A:B+WOL7[!(:'>1+U
M$1G*1"Y!*!@G*7P1X[,!1,,ERJ"0XFM=!'@!$1'V"4V@@?*>:I,"#Y,S4_E/
MJ !NTZK_ ,6C_8+2L0_SYIX$ 1<LCRG\4>BT^KOPV!]@U/5 (55'-4U1!S Y
M)8EYXM14-#.H5T=X5V68UHZM&^P8AS$-*TQNUJ%R142ZA74QKAUB-Q3$U^HQ
M"*CN$F%:I"][NX\'NV^GOJB.S"<6["W86["W86["W86["W86["W86["W86[#
MB;=NPMV%NPMV%@/I".S"86["W86["W86#?()V["W86["W86["W86["W86["W
M86["W86["P<9!/LW86["P&'?4$[=A;L+%$1'!%?PKF+"240P?1",WT0C,:1D
M4P*],71BQ<(]A'N"<HQ">_1*B0485P^=Q!3%Z@JSBEIP3)-D4M'Q=.C/3RC+
M)46&:-C74"X5%%ZH1.(CLPG%NPMV%BCOH"8 83BVXY>PL!V P#E$=F_4S=0;
M808!WTSC^NL&)B[92FT3&WRD+D..N7C$P[!B'.F<<A.<:<S#[RYR3U+@*<)D
M(\,07D0\>9I!E3W,F%2UWN\R&'<<29A'9A-OI@;9@'?$WZB?CH#%YX-I#SJA
M^N4P;92FWSG-E*7?*;G6#(?('.F;G$G.,#&O8)^DJ;I3A<0'89]ET$V+T9"E
M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>exelixis_logoxrgbx2023.jpg
<TEXT>
begin 644 exelixis_logoxrgbx2023.jpg
M_]C_X0TO17AI9@  34T *@    @ # $   ,    !#.0   $!  ,    !"?8
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   A    M $R  (    4    U8=I  0    !    [    20 "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P(#(S+C0@*$UA8VEN=&]S:"D
M,C R,CHP-SHR-2 Q.#HQ,#HR-@      !)    <    $,#(S,: !  ,    !
M  $  * "  0    !   $L* #  0    !   !1P         & 0,  P    $
M!@   1H !0    $   %R 1L !0    $   %Z 2@  P    $  @   @$ !
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MDI__V?_M%2I0:&]T;W-H;W @,RXP #A"24T$!       *AP!6@ #&R5'' (
M  (  !P"!0 617AE;&EX:7-?3&]G;U]21T)?,C R,CA"24T$)0      $.Z*
M+VTF;HFD<OR1I?7(F<@X0DE-!#H      0L    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !0 0P!A &X ;P!N "  :0!8 #8 .  P #  ( !S &4 <@!I &4
M<P      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
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M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 $@    !  $ 2     $  3A"24T$)@
M    #@             _@   .$))300-       $    'CA"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H
M!@       0 R     0!:    !@       0 U     0 M    !@       3A"
M24T#^       <   _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@     _____________________________P/H   X0DE-! @      !
M   !   "0    D      .$))301$       0     @   D    )      #A"
M24T$'@      !      X0DE-!!H      V$    &              %'   $
ML    !8 10!X &4 ; !I '@ :0!S %\ 3 !O &< ;P!? %( 1P!" %\ ,@ P
M #( ,@    $                          0             $L    4<
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<
M    4F=H=&QO;F<   2P    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "\$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M    % !! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #(
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M1T(                  /;6  $     TRU(4" @
M                                           18W!R=    5     S
M9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@
M   49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9
M L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A
M<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,
M8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T
M="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M
M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                 %A96B
M  #S40 !     1;,6%E:(                     !865H@        ;Z(
M #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A
MML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                9&5S8P         N245#(#8Q.38V
M+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="                             &1E<V,         +%)E9F5R96YC
M92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                                  !V:65W       3I/X %%\N !#/
M%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M     0                        */     G-I9R      0U)4(&-U<G8
M       $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9
M %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8
MRP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%,
M 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!
M^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++
M M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#
MTP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^
M!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&
M:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X
M" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)
MSPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O(
M"^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.
M$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^
M$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,3
M0Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F
M%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449
M:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,
M'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@
MF"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\
M)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ**(H
MU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!
M+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R
M*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D
M-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\
MI#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q![D(P
M0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(
M2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN
M3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5
M*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE
M7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<8O!C
M0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J?
M:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMR
MIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE
M>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#
M5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\
MC&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/25
M7Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZN
MGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*H
MQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@L=:R2[+"
MLSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]
MC[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]
MR+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33
MQM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\I
MWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K
M<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*
M^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X (4%D;V)E &1
M 0, $ ," P8               #_VP"$  (" @(" @(" @(# @(" P0# @(#
M! 4$! 0$! 4&!04%!04%!@8'!P@'!P8)"0H*"0D,# P,# P,# P,# P,# P!
M P,#!00%"08&"0T*"0H-#PX.#@X/#PP,# P,#P\,# P,# P/# P,# P,# P,
M# P,# P,# P,# P,# P,# P,#/_" !$( 4<$L ,!$0 "$0$#$0'_Q $/  $
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M P$! A$#$0   +_
M
M
M                                         #%O'^1Z4Y4Y!QL
M
M#X8^^+]SBOS_ *<F?>X_N],@   !T#X_VZT.BO0-K_H?S3O]L0
M                                                      !COXOW
M:W^D.^\4\>Y)JF.?_9^*?_<72<FN=]>@  #A_P WZJI///I2:7:/4TH>?==
M
M    #C\=ZB_.'I[I?R_J@#7,6F^@/.6:.4<3  &B)K-Z)]!]2^=].U_T/YIU
MS
M       C-P3L&N'I'OGX  28YUP"R#N_H0  0:ZG[BA7U=VS:5W]YSS?ROB
M
M     $,^L.UX)]2]Q@ #,_)^*VH^@O-X $:N#<_K=Z/[\D)S/@]F?>WGP
M
M   1[X9SBLOHGT&0 !*OL+KBPWN?HP 8LX_R.JOS[Z1VF6EM_HWS)D/[7P@
M
M    !^5;53>>O2>)>.\E '([XVQ>A_-&1?M_" ZW^']]3WG?TOTSYGU)<=C=
M96 =Q])        #B#A)C?1/8C4   #X=6.SFL     Z:5*:98)F-     !M
MB_W+;L1$NU:F[YZ@<HF85;6<4ON    =6*.=<NL( ^ESF>N>8D<*5-:9QNFO
MX@     NYSUR[$@"O&](&6IQ1D--Z>6H    &R*L;YQ.M7:DD(M<-GH.G_,^
MK6]TAWWH@/TM&8N3<5FWVIU%R>_YQU[\7[H"=/\ =<;^#\]V.6V8.2\6GWW!
MTKE_DO%@-O2]7'0/HS"W%^5\S^G\UOGI+R[V/]WX ,=3%3M\\)3&DL>I>?%;
M@  11M6ORU(I6C&J/S/LNPPSG$ROK:>=;YUB0!C:8K0O3M4.()YUOG*)
M%'&F4);5      VAZ@L=^U I0TR@;:H L4K>XW/0  #045:Y0VFH M I>V&F
M@%0&F=;MJ      #T69;9UB0(CVK0IIEJ!E5/I,QV     J?OG5_>GP$MHM?
M7EJ!7]TYW=$GKGLSX 2'YIP>S'O7SZ /QK?\*7WNN( %?737=\3.N^R_I.GM
MKIV9W9_4X \]VN,;Y@"VBFEG-+@ =3*5=<H9374   #X3-K:X&FF5(D59WIW
MX_8Z@<2BTVF@    \UFV.,4      =@/3OCON@<.>>W7'!$P!I+K<])[5N
M*NKTJBOG] )91:^G+7]@#SZ:XQIF      /U/33COW, JWOG5->@&54^DS'8
M    "@77*+$U EM%KZ\M0.'_ #?JJ(\W^H.K?/\ H ?$V6=Y] 2-YMP,   "
M)O779E?'3?=_U'=?J?*MW](>7]YKD!M#RT;8?0"VBFEG-+@#B#S[ZXQ]F
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M"VBFEG-+@8<F/-]KCK +#ZWN0STU             \TVV.-T 6KTO:530
M    #IB/._KEC&8 _0_, &?HGT&Y;<L   >?+7&-<P!8M6]Q>>@      JUO
MG51>@&54^DS'8    "@/7*+4U EM%KZ\M0 !MJ:5+^=/3../B?= )GQV_P!+
M3 [*ZM$+>KNV8,]3]Q$#<WI;CZ.\Q]^^Q\0  ; \M6V&L MHII9S2X'#'E[V
MP_, ^&?XF>M;R[K;.$3K           /--MCC= $Q*VEY%@  !VR)GK6P
M$=)CS]:X\<  #M9Z'LMLL1(   \^6N,:Y@"3\6G#6P   W4+%ZW  JUOG51>
M@&54^DS'8    "@/7*+4U EM%KZ\M0  ,+<6Y;5CY_\ 1WQ '*_H_/;KZ/\
M,.*N/\DK-Z)]!:( 2][)ZPGWW!TH  !L#RU;8:P"VBFEG-+@"B33*'-J@ #0
M=R)/UM+F+37K;(<2         /--MCC=      S/$^CK+8    5Z7I3/?/4
M#47NYZS"K8   #SY:XQKF     !S!ZB<=P *M;YU47H!E5/I,QV     H#UR
MBU-0);1:^O+4   5X=+]Z16Z^[& &;N5<1Q3Q[DO#_F_2!S7ZORV_P#I/RYS
M_P"S\0  &P/+5MAK +:*:6<TN ,,3'GKUQZR    :R:-;6P4TS;$@
M#S3;8XW0     ,\Q/HHRV    'YGF^UQQ', "4T6O[RU    'GRUQC7,
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M2J:        8IF//!KCU, Y(V1^0!E)/H?RU[A$@  >?+7&-<P!8M6]Q>>@
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M->0?L_# P=Q/F%7'07HL@#G/U_DMV]'^8.S?O^> !L#RU;8:P"VBFEG-+@
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M*GO/'I;9Y: ;O3.VOT7YER%]KX8V!Y:ML-8-9Z$<MI&Q( ZV53Z9UUVIQP
M !^Y976]L^>FX        *6=,^F3     'TR?$VB4OD6)$/[5KFO0 97B;?\
M]-8   /Q*YKTBG-=C(:2U//21$2*CM,\+S      [Y"SRFF88D 07M2!UZ@
M  #L$+%:WE)6P%36F>"YC<0E)%K**7_4 K^Z<[MB1USV;N;UM'[^\YYHY1Q,
M     8FX[R:(?6W:'7_Q_M S5RGB4R^SNJ1M"B_7+4<O"?5;S(K8  #I$Q!>
MU8BS6/MHQZC9&HY\S=$RVK:P2M\PQ(
M                    Q[\;[E2'G+TYMZ7L)[EZ/EAV)UH
M    !MSB#]CF#Z
M      5H=%^@8[\*YS++L7K2P7N3I
M                                          86XORVJ_S]Z.S5RCB=
MH_?WG/<7H
M                    !IB:I?/7I/JWS_I6P>B/-/9?W?/
M                                                           $
M9^"=@UW]+]Z6I^@O-V5>0\;
M                                   &USTJ(\W^H9U=M=-27YUU^
M
M         !#?K+M7KWXOW3I[:Z<
M                                        &!.(<TSSR[AFJ8
M
M
M                                                       __]H
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MC3+QB;C/,:P5*@C&,8<90ED55\!0*%0D++*BX*3& ("&F?3 PMW8#!G,'Z>
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M5U0ZG%827+'Q%YH3\@^].,B"L'2HMR^(^)H'R%#/LW4&ZAG,._@0XUAQ -V
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M<(JG4>['Z"5F^@E9OH)6:4T%628K'L#=@;L#";?0 =F [ 8&WR]@83L(B/\
MN=?5RI<&=X=X81V:2)7&#)_HV_\ NR>%OW^,:1Y8]Z/[$IN6_A<$ ;-*TN&6
M'[MV5V7V(B.S32M"J1J.DOE2)34YRGP_L2GM;]RA(:&>1#R6T!VCPWL2>O2N
MB+:J=4C),ECX<Z]B=1%K_&ZD66.X^Q0),@WD6   ?\:__]H " $#  $% /\
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M/WPXCO@N*Q$J"?OSOWF@3,8=]4!V8H[X?_1^!W "A^AN=(>=4I=LHANPAME
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M[F:WJ:?+\:$_?'3O7_)W&QC\F\T9"0T?"55IY%4SG+):S4[XJE87*5H-!E
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MR401)^UI-@%YHV\,(+8HZJ"P:[SF3H+N\@19CQ 7DX "LT7=Y-U;->[7L?P
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M0?=IE7*%1ZK#FMQ7Y$T>1-$'0D$9C[5>0VHB2E;M^"+VF]0KUJDL!54  "P
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M7L@Y9H\O4"*.ODA3&HJ7&V2IJ&QDF<\[.Q/XN0]NS?E>U9GHI%*&FN=)#5*
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M%;*2NJ9*(PPO*&(>0),S8#=YACV*2T%HK=G*Q=969(S Z_P]45P:"8C68)P
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M@RL#@58'80=1'(M69[))U=SL\XF@4DA94V20OAZB5"5/IX\VEHS19I-^BNT
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M0\C)GU5?/$SR:^[W.H6DM]LIY*JMJ7. 2*)2S,?Q#2\9LKPT?\QDW;=2-_\
MQZ./N8(O3"ZVZ6)]%<WYCI=[)]FGPH:20=S<JN(XX$'488B.ZYF;N=@;3 #
M#8.P)GNRTIDOF5XB+K%$I+U-MUL^H;6@.+CV.\.C0%3B",01SCD6[,U-ORT(
M_=;_ $*G^(H9".L&'.T9&^G;&'/I1W.W5*5E!<(4J**JC.*212*&1E/00<>1
M<OBLWN#H?;O[H\CB_P#7]N\1'(CX(T-/5V?+&7(Z:ZW]YXWA-XJIEWZ<Q[P'
M64U/TC4TN/\ ICE*TD:NR:T8@$J>D'FT$>5^)>:+%$-D%-=*DQ#M=5([I_\
M;H$BXN72I"@C>JZ:AG;7TEZ?0QS<7+K3*1@6HZ>AIV_ZDIP=!)G3.=\S81LC
MNM?/4Q#THG<QC\2Z    #  ; !R'D<[J("SMT ;=(KK?:1J7.7$5XKU?:>0
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D%$%P$,8@B50ZQ* JAR1@-8.BHBA$0!411@ !J  &P#_RV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140566756869328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  02,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>exel-20240102_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="exel-20240102.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0000939767</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-01-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-30235</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Alameda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">837-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M@(1IX01IE5KB).?A9Q_[.7;[6ZG>](8Q0W9)+/3 V1B3WKNN#C<LH?I.IDS
MDY54"3705&M7IXK1* ]*8C?PO+:;4"Z<83^_-U/#OLQ,S 6;*:*S)*%J_\!B
MN1TXOG.Z\<K7&V-ON,-^2M=LSLSOZ4Q!RRU4(IXPH;D41+'5P!GY]P]!TP;D
M;WSA;*O/KHGMRE+*-]N81@/'LT0L9J&Q$A0^WMF8Q;%5 HZ_CZ).\9TV\/SZ
MI/Z4=QXZLZ2:C67\E4=F,W"Z#HG8BF:Q>97;#^S8H9;5"V6L\[]D>WBWV71(
MF&DCDV,P$"1<'#[I[C@09P&-WH6 X!@0Y-R'+\HI'ZFAP[Z26Z+LVZ!F+_*N
MYM$ QX7-RMPH>,HAS@S'\ITI,H,$]%T#>O:N&QYC'PZQP8787ZFX(UYP0P(O
M:/X[W 6,@B4H6()<KX&R_#E::J,@6W]5$1T4FM4*=@K?ZY2&;.# '-5,O3-G
M^,-W?MO[&>%K%'P-3'TX@MD8P:\A3S%=5]'A\2L::X9P- N.)JKS*,,LQY@Q
MQ65$)B(BD/S*#.)*>0;S%-;EL%6PM5#%B3#<[,DK6W.;18!\H4DE68W.M\GS
M]-MT?D.F+^,[!*Q=@+6O 1O#N"D:DZF(V(Y\9/LJ-%S)@Y]>H]=I=Q"L3H'5
MN09KDC"UYF)-?H%XLR%CF:145,+A>G5SK%MP=5&=!3<Q(W)%_.#'Y4]DSL),
M 6@5$"X$/4G ?>=&AF_D^SO/\\%M%/E"XXR1%-;[?$,51MPKB'LXL:*1'<'Y
M/EG*N H4C[<S#L'PO=)1/53H-%9DL@LW5*S9Q250(_0RFC^.?L.8SES>OV::
M/7%(ZDN6+)FJY,%%8-[?-KR@T<*02K/W4:\^(4U%*%4J%;5%^@;F"1@9D0I6
M0 8K%1:LC*K'#E=_G&"0I>/[N&4?(1=T1Z816 =?\3 GQ481E_2:MXV@U6GT
MT&$L:X&/6_B1<!1%4/#TS>F"/,-[Y+.H'CM<TN^V?/*!JB6DX8'N[7I]V](]
MAEN6!_^J^E#@CFT+OF<AMZ(2%9<;Q;"T(HJAE07"OZI"%&C%5)PI^<Y%6#V4
MN.9XA*&51<*_JDH4:#.I#12Q/WAZ>7W@BKUFRPLPMK)0^#4&GY/!B> R"B[0
M;GD82.G_/F[@SS*$,9EMI$ ]#A?I-CJW'3 Z;#M;5H( -_"O4 8,$[::)YDX
M.H>NW-;B0G55/2@+08![^%S&/.3&%LI/,+T5IY6ELD:EEN=LRX_[]$RQVQ"&
MA\'ZRO>T"]ACPZ[@\VI5G;\:O5JRTOH#W*?_0S;5.@.R6L#_=P@(2N</KCP&
M+/9IY;JKB>_>?JSB<,\.D_9@_HG:G:DF,5N!C'?7 4=6A[/NH6%DFI\OE]+
M:36_W# *8V1?@.<K*<VI88^LQ7\<AO\ 4$L#!!0    ( ,)(*%B?H!OPL0(
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M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #"2"A8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( ,)(
M*%@.^_+D[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( ,)(*%B97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ PD@H6)@J\-]0
M!   ?1   !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( ,)(*%B?H!OPL0(  .(,   -              "
M 9,,  !X;"]S='EL97,N>&UL4$L! A0#%     @ PD@H6)>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  .L3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="exel-20240102.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="exel-20240102.htm">exel-20240102.htm</File>
    <File>exel-20240102.xsd</File>
    <File>exel-20240102_lab.xml</File>
    <File>exel-20240102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20240102_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "exel-20240102.htm": {
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20240102",
   "dts": {
    "inline": {
     "local": [
      "exel-20240102.htm"
     ]
    },
    "schema": {
     "local": [
      "exel-20240102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20240102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20240102_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://www.exelixis.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240102.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentPeriodEndDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exel-20240102.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000939767-24-000002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-24-000002-xbrl.zip
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M31NT/ZCRK<%=14P/#$MX)Q19ATZL@/XMV&W(AUHTLC^.,I%ME*1%@XX&7/6
MQCMQDL2#1@4V"G90(GT>IHO0>J8YI7Y07+8'/7%AX+,DR%9.F<-VJ*V8!"L:
MG5HV=G7[VL'K&FLUV]ET;)'@5EF/]!0]TP-& LH0^V\+8'3,8S7%DSM,F(Y#
M&3 DIZ.T,8F'BRU#'@1 $PUO.&;0=#1S>F0A+F+;S+\[GB-!]O[R^CRGMQ1Y
M6Z)@+18>0$0HNDMX&(#B#<6.\;"Y*9&Y!,:P,I8$Z(^:]7'9C)C!*]%=D1CO
MZ01"RL&(]LH\8I]8"CH;24$0W]>MBQMVW;JZO+YASR"M-X/SZO-U^_,) 'IS
MR4#IW(!F86Z)75XSM[(7[+/+]^SFM];+A7]&4>9*\J1Y@W"[]5+Y?L!GZ*7^
M N@%S3P6=]FU&,8J87O99\'!T!,Z8>(6?6]%S2+8;[#MV?2*K,>6L2D+S'B%
M8!..DT8 WU@#F**/PZR 3ZP)+&V)*/<0"L>_\VC$U81Y!^31W\OC3\_1]YW0
M*]+X]2TT_FK%7*X^K)C7:QT'=4[AP;.1@Q[3RE]PT/[JN?9_AN Q\A"(I@5-
M<BSU7Y_B7OS7]8=W?V%PPG18 GO\&&R[51A8*.:.Q!J+Q5V#F,=JW-6$Z'U5
M4?'4^MG$$ZY%3VJ, R47T)+Q<ZEPW/JS]>GLS[/V 3N[:-KKV7D-^M$O>)3!
M^(!!9)#[=4VBV@+&RRLQOM<:<S\AQ*),5CE"&==,#X6/@8& R8C)1#._#_Z]
M4/M?W^9Y?I%8K]J';OV7^R7B+_<)O%+-+M7<>YL=^_ZV==.Z==NMEI]\VA),
M6ZYL-&W*)$\DCT#HK!1&4X9Z3M/E4?+H+/)C!68,1:3;"5@>S7@4)6K2C(-Y
MLP0#W!@N2\10Q;<XS]0>*8/-)$)^Q]6*F.62Y/IQ%JO/XKT,!73N * I7BL4
M_;1*H,TK/Q#[:,3>\/%9&C+VB=#GL7P(6"Y;):]2+=4W0?.W(U0VU+@D%UBL
MV&72%XK]/E)2!])'3*(*GI,A^]\B76Z(IV8\&$B-&5N&O,P,F7W/&#F[;K/6
M8!C&$Z";>1YD%[&]"C4[,\YV&5'85F*=!($26J?_?(+YW$Q:50O';JWBLM^X
M HN2O>,3=L75ESL^611=+S=0]$AT-.'/2W43W^6&1ZUP?!)"YX O;OY@BYC,
MW"(D["[5%1@YDK+@&]I ]<(QX@9Z1W()FL<"<Q7#:N'_R*$QQ]*HKE,XKI<K
MF)E\]@-_4 [0>>^EVT%M,52 5CGD(1-CX8\2>8M^'$@%H??9'FR5X5[W=Y&C
MVB7)[VU. 4CF)TKPN3-W"\>'%6?QQ/>W(*Q/,:B.JWX<+1B9KE<XKI6J%L"]
M-/_+I:AI(.77GVJ>6SW2+!&A&.+^6$0;/&! :>$(52H#SX0#<H"P-HU"?S7Z
M6+VA9E_X7ZB"BP]!N "7H,W5B<>L(\+XCLDN-;X'8<1JUD?6E2'N2VK89"*B
M0 0LB9F6@U&8\$C$(QU.F 9-J[L3&ID.B#MP9CPSW;!A)H(R@GD4X]$D:^O&
M(2R.XU#@231M--O30K /(A(*F/@L@K$C8PN>V)YMP,60^#:A9!FA;=!P:]O@
M_01P%++/D<1S9>?M_]\!;,Y(?RB9 ,K1VAM%J36CE_5$)X[##@?\)7"*.;.5
M"L>__E2OELM']WD:NZ2Z7W]R#YVCY?^G6P0LS.Z1#4=*CY!0@-2N1V#AEKU*
M2C1(+6V0YS!0"LU._(3MN576?'_-O))C0\>-.>\5DD0[#J4/.X]ZY\"V",2F
M]%!^%?0PW1\;I!M<)@:WS$&9S-!#:^SW>=03\]10=FS3\ULFB"LE4#Y@G1PE
MY5%"J\MN%]7N9H11>16$ ?NT_)F-/B@QW')@>7N=_<W(Q/3]C@CE3.N14(\@
ME\-OE%Q*PBKO^9N12]IW!;ELD^.>2;G,4%=IYQ;AC#8U)II08.3-8@AZ(-H,
M:EWBJM1N ]0T5B!AQ_FHNEVIE!Z5C\*1U:?/1]7L:NW^YD?GHVIVZ;#TU/FH
MBKVR=.HK5^<]2)J.\XL!*A!^&O)M$&]BK\+Q#9;HFUH9O\_\D&N]01G?UHGG
ME[9KQ<G+;$\&G3C<T_O?P9XOT@0\';3(9#)X@7=]"=],1=9RZOU)&<!$P5]F
M^BD5X1/7ZQ!CY-JZ"@X_:#[ 5CN)P>__V78<%^.X[-\\' DV!%W7[J]+ISXA
M8;UD#*:<91@K1U_-U,M\[\C)R"NSB$Q)T:*]B+PY'ZIVZR"RP$JXX#K@?Z<D
M>,[5%Y&P3Y^:CZ@7WJUE=!8%:#$*UIDPG^)F8)U\ <$C*#^Y$-22F@%H8&ZB
M =-C/17?)7TT/(<8Z.*:!:(+2U#)D EJ.)7,CEJ(:,"W;KU48GMH<E6/*+"1
M=994;#3$8B-,E1KKU>M8WHJYYDQ8,VDYGQ0MV>FXF6EMUKIG$UN:^,_EZYC4
M1K:)#[2'IMG"AFZ.YSSHYFQF\^^88+MK2!##U"OI62[%9_M K2($JQ^H-8K)
M!QAI0;T Y6D4&"^92HK'FAMJB%E:*YS@XG13&(DF$G=(J$K<2@WC@ =XY"-A
M<-_'&B#LC#=! ZX";>*_P6H'!+RT/9[['K/$;3\O:>:D<H_'-WN-;A@;K#64
M"#EFI98NUDT=)_*!G.D0WM%Q.$J6ASQT%V_;"X'5_$)@7TU56D]8'27X%XMW
M04XT>'C')QJK=9_VUN!N$V9GB1@PSW8\FUT+/0H3RAY> DVGL0*@3/8^)]IF
M#$R$#?;CG/_9R%'I<.?._F7$LHK^JJGH/V!96?<!5MC8;"_[C%R+C):*SGW0
M<'H$G,F!23')"@0L.(@%'D7 QSZEB1+D8!@.9(!KC"(^ G3-L;U*L=Q-I^]*
M#680PZL'S(B64^$+3*PQKTXPE@Y2L8!+3"?JC62 %\COFPE[9YLMT425 SK-
M  "\I2@'('XT#*CJR-3Q=D8:<*:US4Y E@TI0:5'X&?,;QF0TQVI2.H^3 *V
M@##2#C5N7W9DPNIUVZ6U*'&6U2VEG<$   F<7W"V&1I)FZ(-]1[/[(C$#)R!
M+(A)8N.7&/<"Q0;]\K< "%6X:?2O2.A2KJZ;TT":Y)Q9U\\('K<'/9<.QVPS
MT3F$T"F>LL\6QVP005M?#Q.51F!<;ZOI\2SBJ!=3GC9"LWT4!BG4B$RC3C0J
M')QQ%FVK4)T?VRPKA#K.^ %U9)\G^39 (X9A>IF'\/4DK(&$^UYT%%'YH6'I
M9='T@/1YV3+K9M5A2)VB<C;[;@P4PX'(:$E\P'0?>0!YH@/<(8!L H84Y0&H
M,A0!_>T>$<[!Y@!=*XB$<YNCMJ%A?8 ,P@=T3@<H.V/T$N[ Z $)TOD/3)=1
M5BAY1X9F)IH;J$2GR\&X=&7-7"-"7 ^LGCUO?[VS,+N\(<U9G"U(C1Q[AGD-
M=:,]1I(>49FA<0Y]<Y)L5H1A<4!,UEZ:_L_?B?ELM^U9B'&]''LSA8Q[[59S
M'^S1@*S3J4K*G"W3(F!'5"%*%@@M0-(;#SON'J -"U9DF)8 (3R]M'Y SA:/
M,GS"8@3V#&Z=Q+L!^ZD8YWDLF(H-"-4@/DZTCGTY?:^G-4:!JMBIU$#>@ P@
M&WE+Y_'JK9A*9L7,6"IYI<Z[&*B!E)94P%2QTFP/^]'W^R" DWZL8%VT:4#V
M4H$)$"J6H0"%F+Y7\-<^<B[8"R.D=$#P7:R^ "7Z@LA9"? ?R1!9!8,/1\*R
MJ8G@*.!#62DZ'9P0_:X$_"\?R]9BPRJS@HW6-G]@01OI/\IIR<2H0://=/H7
M\ 9:$N1:^4(AYX/0\04X;+@WKA)@"MV7PQ7G_ZI5Q1E)NBB5I;D0PC.<HQ &
M\@@$5Q).$)D2:PVTD<,R,7H:<#\",=/KH4A!9/>YZAEY38538QH$XW_V*@QV
M$$I\^^)GMV3G'[%O%J0.<8Y4_$^IAXZ5G D2V!EP8CR$'2! 8,2EQTI =4B5
MH-V6@+D0H@#VXUY$%!P8PC5F ]AV[.\174E#*+Y1HP"/-;.J,B..KT+O\JFY
MU0H3IF!<D*/CEGXAPQ4./8D38#)\2X?B$PRH@@R+*$AQF1JJM#QH4G-<IC .
ME20^>H1<2?Y%L'!B%" 1R?=Y8*B]C?T]Y;K4J,GX*UG%!W'*CM/D/.&>JSG3
MBH-[.AA.G78.$A<=F'3F 9^P0&*M ^NJ>&#T?@['"FQO^';28;GN'5;+9;>&
M%:[/'!=<8R%4*,9Q*E#\HR::4XO  <U445Q2D;321ZP5BIQ]\JY'[&0XA#,D
MQ8,MR^/P_$#7<.@^82=*H:UGU-2*[M\8F:\R34;#.$I#K*8H)9@KC+V(<V6-
M9-O,3&SV(;X5*B++@BSE)!$B&Y2;-E-3>?HU<(M"?S2@[Q#\^6' +&Z)#<B3
M3'G%G"F,.$?0FS9[)_PO0H7B@%WU[5.;>H$I_X'+D+7\+\!4 ?A>Y]B4ZK5\
M[BZ*9/PF$G<H\M*W(V^YCWXN6C8"V-"GDGP)^ @D"662JD"8R-91G"K-@,R5
MB0DW\]0QZHCD3HAH3E@@?*= 3CG@QM5((37*?4%@!.!>A[%&9C"2A?BD[)33
M*/.UZ(U"<U1MZ^,W1J@G&I <69D2!&2D#'ZP#HV9&4+OX(5&Y\$X@4=)M)8&
M\IG/=9^&XGN,B=%[)!.R*-3JQ<%#U[Z2'9AY*NQ]3E(]<]N;LU/-BJ;,E0?I
MLA@[HE )&@"3:?#H@%$ 8&HF@@N*X91S4!1N%G@DY@ #720(-72,HSS(YSIV
M*2/^1;,_5>9DHY&CC7$:+*IW'>N_\P#/M%>:0S%1GK88)HL1T-6P7H"(H(YN
M%D+[MJ@4#'K,I--1YW&Y0 RBZ?V^/&.$2)T2T@HB>#<)^9V>!KS3*PUD8%!2
MWH0QC$.6TC&&4,SET_E53\ Q$%,GCJI3D!;O91T@I3RB;+R".T[!\EMI+E&8
M YZ)(0-YN0C:XC9.H@CMFNLENOJX2>"P9"C%O8^B\F"B6Z..WC<F]V84M)<I
MZ!.T)L]1N2FZSX-:+=5[!VD8+=6EF;8A=0*?^Y37]XG^TDPID0Z=A!*6R$RH
M.1UYUP?EA4$X=-31S 6JU9F?00\G<W/& R&2-$*OL7JB'X<8N <S3F70&I&,
M\3T9C<C'!,2 -,9H8,X.#/.LX:;3$]TB>+@SBLXAJ=+VR(@A7RN-KX$.Y?.L
M,(LFS!K /V!A(W>9C"?Z/*MEYC1K<,"&=!, ;06,RRK4_/Y**_VUIEAG_ ;O
M\#M+M]9LQ[736_XM?.-LVSCDD\-,,S4D./[2WZ1F&FOF4 */%+B7^(+RZXZB
M+N6"%Y-84]DU$S0UTB## 4J$T1!Y^^=RQ9D-@M$#2:8,D<1,%L>?CZJ49W.N
MRXG-)TVY@F "C4LSP"+#F=P,^@0CDY)(TR)99B8U>%,C]"3%3^8%TY[/TSTO
MD@>[4G%/\0%I!=IJ:JH^-NA0*=>KE4K-+3MX?V=+LL.R)PM(#X5J0X\& Z"
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M;^L3C;AV -H5 (R,@(,  ) #U!  @($0A/H+>(%LPQ3?P0N4"!,^*1#X-AZ
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M__O;B+X@W_$H,<RAZMN?G3:M'VW0?VCC^N'#[3H; 8(A?EBV;9XNX1 &!%@
M;2  S" >8-H) #\XP!$P!#.+&_AQ!,P 74 #O$N!Z4EJQVO_6'[!$63^.-#Y
M$\&/\C/! %Z^'A[;I@!P9XROEPON+^,;B9?<-8DP*'X)2. OD0MH_(CP;37,
M?@0PT5PXS@.-1.&L/ P)0Q#RVW-(B6T@P A^R(@5?:U?9).Y83&^WK^AX!@L
MV@W]([MJFQ.8C(DXL$Z#\,5C=%%>*"P"CW(A:G_:>W<*H=PF)F (+?J>;CS_
M!^R'^6(]=B:B7YS_.\8(YX;Z#0-'>. M$&Z_X6B1*) /%8#7Q^E9&!GN)CKR
M7?1OQ!0G,=C (QYHMUU/T6T;K[>+)GC7!>6*\"5F.@H_%!;_!W*K7?3OY%3.
M;IH8#PSV%^<R;#-HZ/YH(*AQ#.-%N%/@,=[@=(9#_>HX2@_0D?^ I78FILQ_
MP%-A"8GQ+VCB:!/:YB.$L]H,\!//3 2)1Y3$.C51S),=%Z6!GT,@^!'LL'#B
M$2;KWT>6?Q]9_GUD^?>1Y=]'EG\?6?Y]9/GWD>7?1Y9_'UG^?63Y_]R1Y?;J
M?C]Q_6H-$-_I /<KP!' !=Q .X,;:Q[ !#@)PGCP@R-"A(,YYO^!@N>W+3?Q
M&=N[=S( #CX"_-_Z1-]W$H_W5A(7]\*)(0C[ C$DQE,\ .$M+BDF(0X<5@OP
M1B#=47@>9Q2X'U7AG:ZNX^5!NZCP6LL:21AY:Z).HO4"L2CSP&,6R$!WI*(+
MKYHJS^$ I0!/;T\4'L$3X.GAA5,*4.$E"E<"80):G)>'2()W5^'=?D7$QLB$
M1Q.#1?'(BTF)(B4D)'CD%<5DY>10SDA99YE#/(0367$)67$)15$)!24I6259
M69Z=P@L^$.OBJF2FI;/S.+"FPKMCE[^_OYB_M!@&ZR8NJ:BH*"XA)2XE)0I2
MB.).>^$1 :)>N .[$K10."0633R>Y"'4$>!&&J_"R[LCU@7Y0ZHWN 4FRG1!
MBJ,\4)XH+SP.])BD^"XM:-P/XC^Z]A="(Z-_3>KI^8,:AS=#N?YK:AQAIRIN
MAL)A?+%(%$A^X">SMA_^/V'6]@/M^L&.]O#PQ>&Q"#P&^V<AOQ#\9J*WRS]1
M&6P ":5_)0SXIY0!OY/NGO#_$_K=YAU%7)!*KABL)P(T'^V)<$.)G_)&N1%D
M>2MI8E$$C2TP&(_=8-3_:0B/E)R8]*]O+/W"A-("/RJ\A- 4E9 7E9*UD%10
MDI!2DI$0E9!1DI#8)C4"X]T%@4?\B9CXOM-OQ!@7M.OI?X?4R$C)#.7E@B8$
MJZ8' H=3X26>PQ.<N$NP?8B$\-#"('T)(:JOI<+KZXMV49*3U9:35I204Y#3
MU)&4U-(X(J<MI:6@(*^I?4130T9"?E? KXP@1LP%Y%5 24LCI*11HG**2)2H
M#!+I+*H@+840591SE99#R4DH.+M([?+K>^'P""_"$=@V/QKD1\JZ2+K(2R!$
MY9$N<J(RKD@Y445%9P51180$4LX%(2TMH2@+IIB?7:!DCD=@\;[>)EB,*]H#
M=(PUROEW@ITN-/=UWNE%?3.,,]J+EP?TA1+(YN*+1&%W.]<$3!,>:&<L GN:
M1U).C& L(;IVA5BAL#C0I:#[P<@1 WW](Y24B.= 8 ^!*DC_BM?7U/RA&\Y,
M5X-'7UM33E)13DY42DR2D%O Z,.C\1ZHG31SQ ._ WF@">&LY('P<@,=)+IS
M',6K^N=OI Z+;_. S.(_Y8C_(GVGUU!8M!_*10>+\>0A)@PE])_Z05%* 2&I
M( 5Z'X40E5&4D00A&6=1>3E99V<YE**D@BMH_3:_RQ_BX#_AQ_SW@;@M /M/
M0UW\A]EZ:!S8?Z=W7&N.\OGI9&+F4T(@\<2>Q2% [_#N(/_D&@4I21025$K4
M!:D@*2HC[XH254"BY$6=961<I!'2,@H*A!#?YO<_B?+Z?:S**\G**<DJ[([5
M;3(<QA7OC\"BCKB!YO][>6:;$7D2# X4..&*$TW][PSZ]\;</S/H+\GG7QCT
MSU_T_"?FB/_L*O&_]J+X7Z;D710XSQ/)=]<8JCQ_E[_+W^7O\G?YN_Q=_O\K
M/T\IP&6B"J\_KYKJUF=J&W!=[FAB9JRC;ZA-/%*AUC-$>V&@] #@Z87'$A;J
M-L=M><C: "A  < !20! (''>1N8Z%L0OT[4U>0BK>>"W\KUG^^OH3E$]$QX>
MX#\K#$AO+!X ("8@+.T"KFQ ^#P(>_CCO0EXPG>]S,[N!!A*^):7&0LJ",*L
M!-AM&SY$I-F&U0FPBZ>7"P@3=/9V\70AP(T@?,G/E_"Z ,P0A"/\T"A_$.X"
M83X/7T\T"!/>2F'V1"%P $#\'ID/CT*>)/S>AO#-,];"3!.$#P, .;7;+[#S
M+S >%4!\HT@3XWV:^$TVCQ!2F$=245&!1P_E[X'"XT5-P$Y!8%UX-#&>W@BO
MTP"P;3.Q,/[#3ND71_W+QG^S$/IV&YHW)?89A.7E3]R?Z# 9 *"P"/KFRD^<
M<Q( E%\  -9W/W%\:0! !_9;6?LO]K 0XN67,R<T"BE&<.B/\C\2_!OEE^>)
M$<3]< ^/UO;6D8?@-R2X3_7%\N# ,8'B$?UK$/_7C'_6XQ"X/4.!VS.0PPJ,
M,K27&]C=.YLU'K37/^O$_Y+M+V4[KL'"E+D),#N* ?3MS #LVTN A(D*@-FG
M@"V0'_UF2&$%$$:>-??H=MP3RQ]>*X+&$2XX-/%E&D#3S(('Z8OUVVXCOC]#
M"E "=  SL _@ @X 0H H( 7( \J .J -' 6, 0O@..  ((&3@"> !?R!8. ,
M$ %$ U> &T RD ID GG  ^ A4 X\!IX 34 K\!KH!OJ!C\ P\!68 ;X#:Q (
MA Q" V&"[(-P0_@A(A IB )$%:(-,82808Y#G"!N$"^(+R08<@X2#;D&28:D
M0_(@Q9!*R!/("\@;R%O()\@X9 ZR"H5!J:',4$ZH %0<J@ ] C6 6D!/0-V@
M/M! Z'EH+#01F@&]#RV#/H&V0KNA'Z%?H8LP $8%8X'MAXG"%&":,&.8+<P5
MAH6%PJ)@"; ,V -8%:P9U@G[")N$K9# 29A(>$A$291)]$@L29 D/B2A)#$D
MR22Y)&4DC22=))](9D@V26E(.4A%2)5(]4EM2-U(_4DC2!-(LTE+29^1=I,.
MDWZ'P^$L<$&X/%P/?AQ^"AX$CX'?@1?"Z^%OX$/P13(RLGUD(F0J9,9D"#(\
M6019$ME]LCJR#K)ALF5R*G)N<BER'7);<B_RL^0)Y/?(:\D[R$?)URCH*?@I
ME"B,*5PH3E/$46125%&T4PQ3K%$R4 I2JE!:4)ZB/$.92/F \AGE>\IY*BHJ
M7BI%*E,J-%4X52)5$=5SJD]4*]2,U >I-:GMJ7VI8ZESJ.NIWU+/T]#0"-"H
MT]C2X&EB:?)H&F@^T"S3,M&*T>K3NM"&T=ZB+:/MH)VBHZ#CISM"YT 72)=
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M >A+\JM/T?BJ>0-2=?N'$BK',+*A9;G+5J.Z2U\\/KY?^\B'D?M89OTA- R
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MN6F+X;GFWW%%$7W$D;:"&=BO">%,UKFQ!33MB[\^H-O07%]SYE*CK8G#<J9
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M^UOW?K'@CE ?DBA4U+D0>SF$;>,V.*&UMKK8@+V&FO8-RS9"T/3IQRL2)>B
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M@0PLW3.IWWJ]5HE2D=$I)[+D,R8DLE.+>ZXFE\EQN:$OK5WR05JCENZF[!9
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M*U9 0NU456,%(8!+GE$IKRX)^J%LO_I.Q@?"1?N)2_;7%&K'^Z'X+_?("::
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M%UP^544(".SKD^YI?%BJ-N:\ 2NEO0P+H\UJ <URD.V"^!!UF<#4/M[^F'?
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M,7,3N'(-RG?.P(M6+>%Y^B5#@X,'WL_:NG-I^XFF63_4%;GU=L)>E&FVHH0
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M(GJ=D73QKD89'DXLZQV=![8\'VSKY9 5/K*YL@ZE @W@,1WC=G523D[)/L/
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M"S%!JV1-X];)-E\&]C:4>@/?#J2!+FY&3Z)28!QK:.*:.J;LT3#Q0.!MTMF
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MCL8U^R5Q#=K:NH4=T?9'9B]%RBD$C+<$18)G;H6N\]<*BRV7;>%7%2$IO;B
M+K%%1DZR.;\)>:([ 2O926NA^AMY[$?7 \K:#%(F_V^%Z-CYZ!P4AFI:YOF
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M1O]Q,^7B6V;6[,C%J>ET%[P:=$%-E"#P*.^\C/]+#[E_SZQK!S.#0FHM,$U
M<G"YLOQ-QHB^L:[\+8B^C(_>X((SE]5,'C?^9-'[>1*!N8^BJX?DF3L7ANXF
MH*A-@VZ!=\5;5,G6[7Q^1=U$!4M6_)DO\*J#I,'X_]S$J46W+65F#'F<_=O&
M@DDE,]X/6)A*5X\F]\W6Q*U5]?$NUV<VBG_399_\O2Z[\!15%@+"F)0N,60Y
MILJZJVR4%1;>H#=BN@F*G*H\?VO6)15DK#?&D6E22U-6]ZFF]Y2QO Y*4>*E
MF7?*7:C.7A3*MVIKL*H1*5A%A\ UP8L5Y?ZG)^W\62SL$*$\;<7502?U"3R(
MCNAHS0YCD:D%,8$'?G/M;X.%VJ/+@1ICE(QA#9_BYCXUM3-]?W-<@1E[9-DY
M,Z7Y+*MXIUICA()"]E8G?5R3?_-R+OS_>T3!^:+_O97V^X2D_56A$T68DNGH
MO$:_Y37 1!3:6](X&LB.2N=/<K$KK;)+_Y'A3*?MUCP:'.875<V0>@=(S<O]
M"6:#^. VQ<(R:8J[QV]@MM,:?=FM!N3-?\6VTL?H?R>")>X_,^A?O4N\S.P
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M>U,)49F8E/,7V>5#C2W(SL??+ZB_!J%N-9UV+E1,R,"7L ?;WLUS#$6H9I
MM8(;53]K% S4F\<;P6$E$5I0P/U$'GA;!8#WR]-=CX\7KQ?_"U!+ P04
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M3!&ILV7#M9?$[R;FT2Q6R>SW(BF-X6D^G]]FR3)S+V:^#B 4* (TPB' ,<-
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M+O%N,F[D_N?)J_4KR?*WQT]>_1]02P,$%     @ PD@H6+ T-_&L!@  ZC
M !4   !E>&5L+3(P,C0P,3 R7W!R92YX;6S-FM]OXS82Q]_S5_C<UV/,WR*#
M38I<NGL(+NT&NRE:]$48DD-;J"P%LK)Q_ONCE+B;;+*M$!F(7F);HC3#[WPX
M&D[T[L?MNIQ]P693U-7QG!W2^0PK7X>B6A[/?[WZ0,S\QY.#@W?_(N3W_WRZ
MF/U4^YLU5NWLK$%H,<QNBW8U:U<X^ZUN_BR^P.RRA#;6S9J0D_ZRL_KZKBF6
MJW;&*9>[8;NSS5$FE30:@*#W0*0WE#BC&-&1B0# E;3^W\LCY0R+7@(QW%DB
MF45B;):1@(%3I[+ O.AO6A;5GT?='P<;G*7I59O^Y_%\U;;71XO%[>WMX=8U
MY6'=+!><4K'8C9X_#-\^&W\K^M',6KOHS_XU=%.\-##=EBU^__GBLU_A&DA1
M;5JH?&=@4QQM^H,7M8>V5_T?_9I]=T3WB^R&D>X089P(=KC=A/G)P6QV+T=3
ME_@)XZS[_/73^1.3N,6RV!:;0U^O%]V Q5F=@+B$9>=N?WE[=XW'\TVQOB[_
M.K9J,![/NXM)%U?**.^,_O#UXL57^]<-;A(T_7POTH&'>W367N<+;ENL4NC[
M.>ZLE+5_,JCL%*Z;W94E."S[HWG (N_O?.HV;0.^S5$A(*.))R<XD5PR8EFF
MB>N^2BT%NOATZIW;F^1W'Y -^L-E_661;IP"PT7WI=-%])H\,W>OS>O\/DW+
M+W1+\$,)RUPI;CU3D: +:?5(FU8/:$V,4>A 6,VD&^7W$W-/_7X<U=/&S^HF
M8).2R,X>-/Y9A)_B^S!B<0U-NA'QJZ(,NZMC4Z_W$:VVWH=V]Y%)_LYG:=H1
MFP;#Q7U@OCN[?FIMRJW8CQP3]%W:O<2FJ,/[*OR4DF]N7$1CC2:\\UUZZXC3
M*)(JBAH'W@>1C0K^BV8'0<"G"\%X+=\8AO=56[1WGW!9=$I4[2^PQIQ3K4 $
M3B(U@4@=#'$L Y()1$F%I4&I42R\9'40"F*Z*(Q6<A(DG"6M&BC/TP-Q^S^\
MRZ6+H(.BA"D34UZ#2  <D.BCPH!@=)1[0.$;LX-8D%-G88R6DX#A_1J;9:K>
M_]O4M^WJK%Y?0W67ATRB3 X32@U+U7,(Q'&3Y D*T-!,&!KV@,2+Q@>!H:8.
MQGA=WQB/S^AOFC01QMU5T9:8@[-6NZ2'%<80Z90D5FI!,ADB2)9Q!6P4$]]:
M' 2"GBX(HQ1\X^A?-=#MZ3_?K5U=Y@C1*,\E29MKW6'KB(FIX@$5O5?,4IW!
MJ- _,3<H[METX_YZ[2:RY-]O_0JJ)?;E31:E,]A-6V!&9*8- 9&2%X('10-H
MH<U>EOUCJX,0,--%8+22DZ@-/A0E_G*S=MCDE(*.F<H(2X5,5^1: @B:4*^]
M9!B8S,0>"H*O%@<18*=+P"@%)Q']\\K7S77=]*)_3MKC67V3JMV[LSI@'CGC
MP0J7'E[.IT+7!P(9.J)\9@%DYO5>@/A;)X:UE^C4(=F?T)/@Y@JVYR')5\3B
MOF/]L  D=UQ'EZ4P^S210&E*?S$2(02W7)N8Q7%%Q-^:'\;*A'N1^Q-W$I2<
MAI!BL'GXN"@J9#G7R#53EO@>=4-M4L4R$BQE8'AFG=X'(2^8'D;'A)N4^Q%U
M2F2<I:\?FZOZMLHI0$IR&27,.D&D-1D!X"%5U)F*7'D Y??'Q5?#PZB8?+]R
MG*!38J)_.'YL+IOZ2U%YS$- *G@4Q*!&(C'MJAV$]-.SZ)U4VL,^.I<O6Q]&
MQ^0[F'N0=DJ(7-:;%LH_BNN^> *J;!0\5=G!I5EDS!-C="2:.JL@1 !!]P?(
M$]O#\)A\'W.TK&\,1Y?U3AN$WF^>4=3*4,(C2WG/)2G *4X<9T%;:R$Z/@J'
MQ]:& 3#A_N6KI7OCD'=ORI27J[K:;;W3$XTY2P7Q0&57'*<M%%6:1.$T8Y'3
M[LV0,6'_UN*PT$^XA3E*PC<._V]-T;98G=7K]4WUL$O:Y%9+[X!QXIUB:1L=
M4LJ27G0;I+1#HIGQ@*,8>-'L,! FW,@<+^9;][3KLO!%6U3+GU.!TQ10YH$I
MI;*4RJ@*'<LL$*>L(D8+%X+J_A,S;IOYW.8P#B;<SAPIXQM#<-E@1S"FPK9[
MD^>J>Q>P^1B3'[EFG%D;@&1<I.TQ TU 8DR5C:02.>-FY!;B^[:'O1@UX?;E
MGF2=%ASGF\T--H_G@LQGZ1&7$:M=DL>*D'9!0A)@*=5I=([2<?GBGSP8!LJ$
M>Y=[E7@BKU9>I;&Y8SR+GBH2?$A^T^B(40P(E5*D4T9(-0Z-Q]:&83#A)N6K
MI=M;R-\MGFEWD0Z<'#R<Z/YTK\:?'/P?4$L#!!0    ( ,)(*%A/*7E<6"8
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M;G6(9SS GLL)P.M::K#VR)XS.\%8G2%T]%ABKANSLZD>DZK@?T>QR8:X78+
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M?NJ+5\(LGP,H7ZL7[B)2#!6$7# 3$PPUQT4C:65G&(/=A4&N+&8=@S'"8%:
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M;"TR,#(T,#$P,BYH=&U02P$"% ,4    " #"2"A80@+<B' "  !]!P  $0
M            @ %_%@  97AE;"TR,#(T,#$P,BYX<V102P$"% ,4    " #"
M2"A8U=T09:JG  "'V   %               @ $>&0  97AE;"TR,#(T,#$P
M,E]G,2YJ<&=02P$"% ,4    " #"2"A8XI.4#W4*  !+7@  %0
M    @ 'ZP   97AE;"TR,#(T,#$P,E]L86(N>&UL4$L! A0#%     @ PD@H
M6+ T-_&L!@  ZC   !4              ( !HLL  &5X96PM,C R-# Q,#)?
M<')E+GAM;%!+ 0(4 Q0    ( ,)(*%A/*7E<6"8  '+G   :
M  "  8'2  !E>&5L,C R-# Q,#AE>&AI8FET.3DQ+FAT;5!+!08     !@ &
+ (X!   1^0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
